Turkish Cognitive Self-Efficacy Questionnaire in Parkinson's Disease
ConditionParkinson Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-85
SponsorAcibadem University
About this trial
This study aims to evaluate the validity and reliability of the Turkish version of the Cognitive Self-Efficacy Questionnaire in individuals with Parkinson's disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Clinical diagnosis of Parkinson's disease
Hoehn and Yahr stage 1-3
Age 40 to 85 years
Mini-Mental State Examination (MMSE) score ≥24
Disqualifiers
Major depressive disorder or psychotic disorder
Advanced dementia
Severe visual impairment that may interfere with study assessments
Severe hearing impairment that may interfere with study assessments
Trial population
The study population will consist of individuals diagnosed with Parkinson's disease who are attending the Movement Disorders Outpatient Clinic at the Department of Neurology, Istanbul Cerrahpaşa Faculty of Medicine Hospital. Eligible participants will be between 40 and 85 years of age, have sufficient cognitive function to communicate (MMSE ≥ 24), and provide informed consent. A total of 100 patients will be recruited for the study.
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Cognitive Self-Efficacy Questionnaire (Turkish Version)
Other interventionParticipants will complete the Turkish version of the Cognitive Self-Efficacy Questionnaire to assess cognitive self-efficacy. The questionnaire will be administered for the evaluation of its validity and reliability in individuals with Parkinson's disease.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Validity and Reliability of the Turkish Version of the Cognitive Self-Efficacy Questionnaire (CSEQ)
Assessment of the psychometric properties of the Turkish version of the CSEQ in individuals with Parkinson's disease, including internal consistency (Cronbach's alpha), test-retest reliability (intraclass correlation coefficient), and construct validity through factor and correlation analyses.
Time frame
Baseline and 14-21 days for test-retest assessmentSecondary outcomes
1
Self-Efficacy for Managing Chronic Disease (6-Item Scale)
Assessment of perceived self-efficacy in managing chronic disease using the 6-Item Self-Efficacy for Managing Chronic Disease Scale. The scale evaluates individuals' confidence in managing symptoms such as pain, fatigue, emotional distress, and disease-related problems. It consists of 6 items scored on a 10-point Likert scale (1 = not at all confident, 10 = totally confident), with the total score calculated as the mean of all items. Higher scores indicate greater self-efficacy in disease management. The validated Turkish version will be used.
Time frame
Baseline2
Montreal Cognitive Assessment (MoCA-TR)
Cognitive function will be assessed using the Turkish version of the Montreal Cognitive Assessment (MoCA-TR). This screening tool evaluates multiple cognitive domains including visuospatial/executive functions, naming, attention, language, abstraction, delayed recall, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive function. The validated Turkish version for Parkinson's disease will be used.
Time frame
BaselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov